Tag - EVOK

Feature

Evoke Pharma’s Gimoti NDA targets female gastroparesis patients with novel delivery approach

By Len Zehr Evoke Pharma’s (NASDAQ:EVOK) discovery that its metoclopramide nasal spray, known as Gimoti, to treat symptoms of gastroparesis, a delayed emptying of stomach contents, reduced symptoms in women, but not in...

August 21, 2018

Developments

FDA accepts Evoke Pharma NDA for Gimoti; PDUFA date April 1

The FDA has accepted for review Evoke Pharma’s (NASDAQ:EVOK) 505(b)(2) NDA for Gimoti, the company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic...

August 16, 2018

Tag - EVOK

Evoke Pharma’s Gimoti NDA targets female gastroparesis patients with novel delivery approach

FDA accepts Evoke Pharma NDA for Gimoti; PDUFA date April 1

General

More